Home/Kuleon Bioscience/David Gilles

DG

David Gilles

Co-Founder, CTO

Kuleon Bioscience

Therapeutic Areas

Neuropsychiatry Substance Use Disorders Schizophrenia Obesity Pain Neurodegeneration

Kuleon Bioscience Pipeline

Drug	Indication	Phase
Substance Use Disorder Program	Alcohol and Drug Abuse (cocaine, nicotine, methamphetamine)	Pre-clinical

Leadership Team at Kuleon Bioscience

Allen C. Barbieri

Co-Founder, CEO

Co-Founder, COO

Dr. Paul Tarantino

Chief Scientific Officer–ADVISOR

Dr. Andy Mattai

Chief Medical Officer

View full Kuleon Bioscience profile